截至目前，中国已有5支疫苗正在阿联酋、巴西、巴基斯坦、秘鲁等多国开展III期临床试验。
2020年11月18日，外交部发言人赵立坚主持例行记者会，有记者问：近期，多国企业新冠肺炎疫苗研发取得了新的进展。我们知道，中国有几家企业的疫苗也在多国开展临床试验，你可否介绍更多情况？中方参与疫苗国际合作进展如何？
Q: Vaccine R&D companies in multiple countries have achieved new progress in COVID-19 vaccine development. We know some Chinese vaccine candidates are under clinical trials in many countries. Can you give us more details on that? And how is China's participation in global vaccine cooperation going?
赵立坚：感谢你对中国相关企业疫苗研发进展的关注。疫苗是抵御新冠病毒的有力武器。中国疫苗研发进展可以用两个“五”来概括：
Zhao Lijian: Thank you for your attention on Chinese vaccine R&D. Vaccines are powerful weapons against the coronavirus. China's vaccine development progress can be summed up in two "fives" :
第一个“五”，新冠肺炎疫情发生以来，中国政府第一时间布局了灭活疫苗、重组蛋白疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗五条技术路线，规范有序开展研发工作。第二个“五”，中国已有5支疫苗正在阿联酋、巴西、巴基斯坦、秘鲁等多国开展III期临床试验，另有多支疫苗正在加紧推进I、II期临床试验。
First, after the pandemic broke out, the Chinese government at the earliest time possible laid out five technical routes including inactivated vaccines, recombinant vaccines, adenovirus-based vaccines, live-attenuated vaccines and nucleic acid vaccines. Vaccine research and development has been carried out in an orderly manner. Second, five Chinese vaccine candidates are under clinical trials in countries including the UAE, Brazil, Pakistan and Peru, and phase one and phase two clinical trials of some other vaccines are accelerated.
中国疫苗研发单位和广大科研工作者严格依据科学规律和监管要求，夜以继日、全力以赴推进疫苗研发，为此付出艰辛努力。我和大家一样都期待着能够尽早听到他们的好消息。
Following scientific rules and regulations, Chinese researchers and scientists have been working around the clock and making arduous efforts on the vaccines. Like you all, I look forward to hearing good news about them as soon as possible.
关于疫苗国际合作，中国政府和企业一直积极通过多双边渠道参与疫苗国际合作。除了刚才提到的同有关国家合作开展疫苗研发外，中方也同世界卫生组织、全球疫苗免疫联盟、流行病防范创新联盟等国际组织保持密切沟通与合作，加入了世卫组织“全球合作加速开发、生产、公平获取新冠肺炎防控新工具”倡议和“团结计划”国际多中心临床试验。中方还加入了“新冠疫苗实施计划”，以促进疫苗公平分配，确保为发展中国家提供疫苗，同时带动更多有能力的国家支持“实施计划”。中方期待中国疫苗研发完成后能够尽早被纳入“实施计划”采购清单，为实现疫苗在发展中国家的可及性和可负担性做出自己的贡献。
The Chinese government and companies have been proactively participating in international cooperation on vaccines through bilateral and multilateral channels. Besides cooperation with the countries I talked about earlier, China is also in close communication and cooperation with international organizations such as the WHO, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations. We are part of the WHO-sponsored Access to COVID-19 Tools (ACT) Accelerator initiative and the Solidarity Trial for COVID-19 treatments. China has also joined COVAX to promote fair distribution of vaccines, ensure the provision of vaccines for developing countries, and encourage more capable countries to support COVAX. We hope Chinese vaccines will be included in COVAX's procurement list as soon as possible after their development, which will contribute to the accessibility and affordability of vaccines in developing countries.
关于疫苗国际合作，中国政府和企业一直积极通过多双边渠道参与疫苗国际合作。除了刚才提到的同有关国家合作开展疫苗研发外，中方也同世界卫生组织、全球疫苗免疫联盟、流行病防范创新联盟等国际组织保持密切沟通与合作，加入了世卫组织“全球合作加速开发、生产、公平获取新冠肺炎防控新工具”倡议和“团结计划”国际多中心临床试验。中方还加入了“新冠疫苗实施计划”，以促进疫苗公平分配，确保为发展中国家提供疫苗。同时带动更多有能力的国家支持“实施计划”。中方期待中国疫苗研发完成后能够尽早被纳入“实施计划”采购的清单，为实现疫苗在发展中国家的可及性和可负担性作出中国贡献。
来源：外交部、外交部发言人办公室、环球网
编辑：熊文博
